EGF Monoclonal Antibody (1H11), Invitrogen™

Description

• The M805 anti-EGF antibody (Clone 1H11) has successfully been paired as the coating antibody in a sandwich ELISA with detection antibody M806B (biotinylated conjugate of Clone 3A8)
• Typical dilutions for sandwich ELISA include 1-3 μgs/mL for coating and 0.125-0.5 μg/mL for detection
• EGF (Epidermal growth factor) exerts its actions by binding to the EGF Receptor, a 170 kDa protein kinase
• Activation of EGFR initiates diverse cellular pathways in response to toxic environmental stimuli, or to EGF binding to the receptor, the EGFR forms homo- or heterodimers with other family members
• Each dimeric receptor complex initiates a distinct signaling pathway by recruiting different Src homology 2 (SH2) containing effector proteins
• EGF is far and wide expressed in kidney, cerebrum, prostrate and salivary glands
• EGF acts as a potent mitogenic factor and the phosphorylated receptor recruits adapter proteins like GRB2 that activates complex downstream signaling cascades
• EGF activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STAT modules
• Research studies suggest the protein may also play important role in activating the NF-kappa-B signaling cascade
• Defects in the EGGF gene are the cause of hypomagnesemia type 4 and dysregulation has been associated with the growth and progression of certain cancers.